


Listing of the Claims

The claims in this application remain, without amendment, as follows:

1.-26. (canceled)

27. (previously presented) A polymeric composition comprising a crosslinked amine polymer, wherein said polymer comprises a crosslinked amine, said amine being at least one of




and said amine being crosslinked with a crosslinking agent.

28. (previously presented) The polymeric composition as recited in claims 27, 44 or 47 wherein said crosslinking agent is 1,3-dichloropropane or epichlorohydrin.


29. - 43. (canceled)

44. (previously presented) A polymeric composition comprising a crosslinked amine polymer, the polymer comprising a crosslinked amine,



wherein n is 3, 4 or 5, and the amine is crosslinked with a crosslinking agent.

45. (previously presented) The polymeric composition of claim 44 wherein n is 3.
46. (previously presented) The polymeric composition of claim 44 wherein n is 5.
47. (previously presented) A polymeric composition comprising a crosslinked amine polymer, the polymer comprising a crosslinked amine,



wherein the amine is crosslinked with a crosslinking agent.

48. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinking agent is a compound having at least two functional groups, each functional group being

Application No. 10/806,495

Office Action mailed: November 2, 2006

Response to Office Action date: December 20, 2006

selected from halogen, carbonyl, epoxy, ester, acid anhydride, acid halide, isocyanate, vinyl, and chloroformate.

49. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinking agent is epichlorohydrin.

50. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the molar ratio of crosslinking agent to amine ranges from about 0.2 to about 10.

51. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the molar ratio of crosslinking agent to amine ranges from about 0.5 to about 5.

52. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer is insoluble in a physiological isotonic buffer.

53. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer has a swelling ratio in physiological isotonic buffer ranging from about 1.2 to about 100.

54. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer has a swelling ratio in physiological isotonic buffer ranging from about 2 to 20.

55. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer has a phosphate binding capacity in a non-interfering buffer ranging from about 0.5 mmol/g to about 10 mmol/g.

56. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer has a phosphate binding capacity in a non-interfering buffer ranging from about 2.5 mmol/g to about 8 mmol/g.

57. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the crosslinked amine polymer has a phosphate binding capacity in a non-interfering buffer ranging from about 3 mmol/g to about 6 mmol/g.

58. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the polymer is a copolymer comprising several different amines as crosslinked amine moieties.


59. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the polymer is a copolymer further comprising a diamine, a triamine or a tetramine as crosslinked amine moieties.

60. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the polymer is a copolymer further comprising a diamine as crosslinked amine moieties.

61. (previously presented) The polymeric composition of claims 27, 44 or 47 wherein the polymer is a copolymer further comprising 1,3diaminopropane as crosslinked amine moieties.

62. (previously presented) The polymeric composition of claim 47 wherein the crosslinking agent is epichlorohydrin, the molar ratio of crosslinking agent to amine ranges from about 0.2 to about 5, the polymer is insoluble in a physiological isotonic buffer, the polymer has a swelling ratio in physiological isotonic buffer ranging from about 2 to 20, and the polymer has a binding capacity in a non-interfering buffer ranging from about 2.5 mmol/g to about 8 mmol/g.

63. (previously presented) A polymeric composition comprising a crosslinked amine polymer in bead form, the polymer comprising repeat units derived from polymerization of an amine and a crosslinking agent, the amine having the formula



wherein n is 3, 4 or 5.

64. (previously presented) The polymeric composition of claim 63 wherein the polymer has a phosphate binding capacity in a non-interfering buffer ranging from about 0.5 mmol/g to about 10 mmol/g.

65. (previously presented) The polymeric composition of claim 63 wherein the polymer has a phosphate binding capacity in a human jejunal chyme aspirate ranging from about 0.5 mmol/g to about 10 mmol/g.

66. (previously presented) The polymeric composition of claim 63 wherein the polymer has a phosphate binding capacity *in vivo* in dialysis patients ranging from about 0.5 mmol/g to about 10 mmol/g.

67. (previously presented) The polymeric composition of claim 63 wherein the molar ratio of crosslinking agent to amine ranges from about 0.2 to about 10, the polymer is insoluble in a physiological isotonic buffer, the polymer has a swelling ratio in physiological isotonic buffer ranging from about 2 to 20, and the polymer has a phosphate binding capacity in a non-interfering buffer ranging from about 0.5 mmol/g to about 10 mmol/g.

68. (previously presented) The polymeric composition of any of claims 63 through 67 wherein n is 3.

69. (previously presented) The polymeric composition of any of claims 63 through 67 wherein n is 4.

70. (previously presented) The polymeric composition of any of claims 63 through 67 wherein n is 5.

[NO FURTHER ENTRIES THIS PAGE;
AMENDMENTS TO THE SPECIFICATION BEGIN ON THE NEXT PAGE]